Oropouche's 2024-2025 Expansion in the Americas Exposes a Surveillance Geography That Dengue Counts Alone Do Not Explain
Oropouche virus disease is being treated as an emerging arboviral threat in the Americas, but the public-health question is not simply whether reported case counts are rising. The harder question is whether recent detection follows the established dengue surveillance footprint or reveals a different epidemic geography. We compiled PAHO/WHO Oropouche case counts for 2024 and 2025 through epidemiological week 30, PAHO dengue situation-report counts through epidemiological week 25 of 2025, and Brazil state-level Oropouche counts from the August 2025 PAHO update. The analysis is descriptive, because public weekly Oropouche line lists were not available. The signal is still sharp. Autochthonous Oropouche reports in 2025 remained Brazil-dominated: Brazil accounted for 93.0% of reported regional autochthonous cases. Yet within Brazil, 98.8% of the state-level burden in the PAHO update occurred in states classified here as outside the historic Amazon-centered frame, with Espirito Santo and Rio de Janeiro alone accounting for 74.2% of reported Brazilian cases. Panama also moved from 16 reported autochthonous cases in 2024 to 501 in 2025. A dengue comparator showed that Oropouche detection is not a simple function of dengue burden: Panama's Oropouche-to-dengue ratio was far higher than Brazil's, while several high-dengue countries had no reported Oropouche signal in the compiled update. These findings argue for targeted Oropouche testing in arboviral syndromic surveillance, especially where dengue-like illness is common but dengue-confirmed fractions, travel links, or unusual neurologic or pregnancy outcomes are discordant.
Reviews
This paper asks a well-posed public-health question: whether the apparent 2024–2025 rise in reported Oropouche virus disease reflects the established dengue surveillance footprint or instead reveals a distinct “surveillance geography.” Using transcribed PAHO/WHO situation-report counts (Oropouche through EW30 2025; dengue through EW25 2025) plus a Brazil state-level breakdown from an August 2025 PAHO update, the authors provide a clear descriptive set of ratios and shares. The main empirical support is the reported concentration of 2025 autochthonous Oropouche in Brazil (93.0% regionally), the striking within-Brazil redistribution in the PAHO update (98.8% of state-level burden in “non-Amazon” states; Espírito Santo and Rio de Janeiro 74.2%), and the contrast between Panama’s Oropouche-to-dengue ratio and Brazil’s alongside “high-dengue/no-Oropouche” countries—patterns that plausibly indicate that Oropouche detection is not simply proportional to dengue burden. The key weakness is that the analysis is constrained to aggregated, partially non-aligned surveillance products (different epidemiological-week cutoffs; unclear comparability of case definitions/testing intensity across countries; and a single-time Brazil state snapshot), making it hard to distinguish true epidemiologic expansion from differential ascertainment, reporting delays, or intensified testing triggered by alerts. The “outside the historic Amazon-centered frame” classification is also methodologically underspecified in the excerpt and could be sensitive to how “historic frame” is defined. Given these limitations, the conclusion is justified only at a cautious level: the data support that reported Oropouche patterns are not trivially explained by dengue counts alone and that targeted testing in syndromic arboviral surveillance is reasonable; they do not yet support stronger claims about changed transmission ecology or systematic surveillance failure without additional denominators (testing volume/pos